Skip to main content

Market Overview

Altimmune's Shares Are Trading Higher On Intranasal COVID-19 Vaccine Candidate's Promising Action In Animal Studies

Share:

Altimmune Inc (NASDAQ: ALT) has reported additional preclinical data for COVID-19 vaccine candidate, AdCOVID.

  • The data showed that a single intranasal dose of AdCOVID provided 100% protection against the SARS-CoV-2 virus.
  • The studies showed that all animals that received AdCOVID survived and had no observed weight loss.
  • Initial immunogenicity analysis showed mean antibody levels of about 1 mg/mL, suggesting that the serum IgG antibody response against the spike protein was robust.
  • In a separate lab study, a single intranasal dose of AdCOVID resulted in a greater than a 1000-fold reduction in replicating virus in the nasal cavity and respiratory tract following the infection.
  • In February, the FDA signed off the company's investigational new drug application for commencing the Phase 1 study of AdCOVID.
  • The studies had previously demonstrated that serum IgG and respiratory mucosal IgA titers in mice treated with AdCOVID were maintained for at least six months following a single intranasal vaccination. The memory B cells specific for spike antigen were found in the lymph nodes when assessed 5.5 months post-vaccination.
  • Together, these new data demonstrate that a single vaccination with AdCOVID in preclinical models leads to a sustained systemic and mucosal immune response against the SARS-CoV-2 virus.
  • On Friday, Lonza Group, the company's manufacturing partner, said it would dedicate a manufacturing suite for clinical and commercial production of AdCOVID at its facility near Houston, Texas.
  • Price Action: ALT shares increased 9.9% at $18.4 in premarket on the last check Monday.
 

Related Articles (ALT)

View Comments and Join the Discussion!

Posted-In: COVID-19 VaccineBiotech News Health Care Contracts Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com